AI in Oncology · AI Models
A researcher-grade catalog of AI models, datasets and open data needs in oncology — every card structured, sourced and dated.
Filter by task, data type, cancer, availability and regulatory status. Each card follows one model-card standard and links to Hugging Face, code, papers and the datasets it was trained or tested on. { } export JSON
HLAthena
Presentation predictor trained on the mono-allelic peptidome of 95 cell lines — 186,464 peptides across 95 HLA alleles, fifteen of which had no described motif before — which is the dataset that changed this field more than any architectural idea.
MHCflurry 2.0 2.0
Open-source pan-allele presentation predictor whose distinctive idea is a separate antigen-processing model: it reads the peptide together with fifteen amino acids of flanking sequence on each side, because the proteasome cut depends on what lies around the cut site.
MHCnuggets 2.x
Allele-specific LSTM networks — one per allele, 148 for class I — that read peptides letter by letter, so no alignment or padding is needed, and that are trained by transfer learning from the data-richest allele.
MixMHCpred 3.0 3.0
Position-weight-matrix predictor built on the observation that class I ligands show almost no dependence between positions; version 3.0 closes the circle by having a neural network predict the matrix from the same 34 groove residues.
NetMHCIIpan-4.0 4.0
The class II counterpart of NetMHCpan, released in the same paper: predicts presentation by HLA-DR, -DQ and -DP, whose groove is open at both ends, so peptides are longer and the binding core has to be found inside a longer sequence.
NetMHCpan-4.1 4.1
The reference pan-allele predictor of MHC class I antigen presentation: one small neural network covers more than 11,000 MHC molecules because the groove itself is part of the input — a 34-residue pseudosequence next to the peptide.
Cards follow the cancer3.ai model-card standard: AI_MODEL_CARD_STANDARD.md. Corrections and new entries: contact the editorial team; every fact needs a public source.
This page is educational — it is not medical advice and does not replace consultation with an oncologist. Diagnostic and treatment decisions are made solely by specialist physicians.